Snips & notes | Biotech Message Board Posts

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  33941 of 34539  at  8/10/2020 8:42:14 AM  by

minxmrphd


 In response to msg 33939 by  minxmrphd
view thread

Re: Snips & notes

 

$BXRX $100M shelf

$VSTM Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors.$70M upfront

$KODK Eastman Kodak's $765 million U.S. loan agreement on hold after recent allegations

$GH TP $125 FDA approval landmark event, says Canaccord 08:19 GH Canaccord analyst Mark Massaro said the FDA approval for Guardant360 for comprehensive genomic profiling in patients with solid tumor cancer, is a landmark event in precision medicine. He expects the FDA approval to serve as a major catalyst to drive adoption from medical oncologists that were skeptical of its performance versus standard-of-care tissue based tests. Massaro reiterated his Buy rating and $125 price target on Guardant shares



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 13     Views: 174
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
33942 Re: Snips & notes minxmrphd 12 8/10/2020 8:52:37 AM






Financial Market Data provided by
.


Loading...